1. Home
  2. SCYX vs PTLE Comparison

SCYX vs PTLE Comparison

Compare SCYX & PTLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • PTLE
  • Stock Information
  • Founded
  • SCYX 1999
  • PTLE 2013
  • Country
  • SCYX United States
  • PTLE Singapore
  • Employees
  • SCYX N/A
  • PTLE N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • PTLE Oil Refining/Marketing
  • Sector
  • SCYX Health Care
  • PTLE Energy
  • Exchange
  • SCYX Nasdaq
  • PTLE Nasdaq
  • Market Cap
  • SCYX 50.3M
  • PTLE 56.3M
  • IPO Year
  • SCYX 2014
  • PTLE 2024
  • Fundamental
  • Price
  • SCYX $1.02
  • PTLE $10.30
  • Analyst Decision
  • SCYX Buy
  • PTLE
  • Analyst Count
  • SCYX 1
  • PTLE 0
  • Target Price
  • SCYX N/A
  • PTLE N/A
  • AVG Volume (30 Days)
  • SCYX 210.1K
  • PTLE 774.0K
  • Earning Date
  • SCYX 11-06-2024
  • PTLE 02-21-2025
  • Dividend Yield
  • SCYX N/A
  • PTLE N/A
  • EPS Growth
  • SCYX N/A
  • PTLE N/A
  • EPS
  • SCYX N/A
  • PTLE 0.08
  • Revenue
  • SCYX $8,566,000.00
  • PTLE $102,106,509.00
  • Revenue This Year
  • SCYX N/A
  • PTLE N/A
  • Revenue Next Year
  • SCYX $405.82
  • PTLE N/A
  • P/E Ratio
  • SCYX N/A
  • PTLE $118.38
  • Revenue Growth
  • SCYX N/A
  • PTLE 36.47
  • 52 Week Low
  • SCYX $0.90
  • PTLE $2.01
  • 52 Week High
  • SCYX $3.07
  • PTLE $10.30
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 34.82
  • PTLE N/A
  • Support Level
  • SCYX $0.90
  • PTLE N/A
  • Resistance Level
  • SCYX $1.04
  • PTLE N/A
  • Average True Range (ATR)
  • SCYX 0.07
  • PTLE 0.00
  • MACD
  • SCYX -0.01
  • PTLE 0.00
  • Stochastic Oscillator
  • SCYX 34.10
  • PTLE 0.00

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About PTLE PTL LTD Ordinary Shares

PTL Ltd is a holding company. Through its subsidiaries, it is an established bunkering facilitator providing marine fuel logistics services for vessel refuelling, primarily serving the Asia Pacific market. As a bunker facilitator, the Group's services mainly involve facilitating with its suppliers to supply fuel for the use by the customers' vessels at various ports along their voyages in the Asia Pacific region; arranging vessel refuelling activities at competitive pricing to the customers; offering trade credit to the customers for vessel refuelling; handling unforeseeable circumstances faced by the customers and providing contingency solutions to the customers in a timely manner; and handling disputes, mainly in relation to quality and quantity issues on marine fuel, if any.

Share on Social Networks: